On November 4, 2025, Phathom Pharmaceuticals, Inc. announced the dosing of the first patient in their Phase 2 trial for VOQUEZNA as a treatment for eosinophilic esophagitis, aiming to enroll 80 adults. This study includes a 12-week initial phase followed by a 12-week extension phase with results expected in 2027.